Surrogate infection model predicts optimal alveolar macrophage number for clearance of Aspergillus fumigatus infections.


Journal

NPJ systems biology and applications
ISSN: 2056-7189
Titre abrégé: NPJ Syst Biol Appl
Pays: England
ID NLM: 101677786

Informations de publication

Date de publication:
10 04 2023
Historique:
received: 02 09 2022
accepted: 17 02 2023
medline: 12 4 2023
entrez: 10 4 2023
pubmed: 11 4 2023
Statut: epublish

Résumé

The immune system has to fight off hundreds of microbial invaders every day, such as the human-pathogenic fungus Aspergillus fumigatus. The fungal conidia can reach the lower respiratory tract, swell and form hyphae within six hours causing life-threatening invasive aspergillosis. Invading pathogens are continuously recognized and eliminated by alveolar macrophages (AM). Their number plays an essential role, but remains controversial with measurements varying by a factor greater than ten for the human lung. We here investigate the impact of the AM number on the clearance of A. fumigatus conidia in humans and mice using analytical and numerical modeling approaches. A three-dimensional to-scale hybrid agent-based model (hABM) of the human and murine alveolus allowed us to simulate millions of virtual infection scenarios, and to gain quantitative insights into the infection dynamics for varying AM numbers and infection doses. Since hABM simulations are computationally expensive, we derived and trained an analytical surrogate infection model on the large dataset of numerical simulations. This enables reducing the number of hABM simulations while still providing (i) accurate and immediate predictions on infection progression, (ii) quantitative hypotheses on the infection dynamics under healthy and immunocompromised conditions, and (iii) optimal AM numbers for combating A. fumigatus infections in humans and mice.

Identifiants

pubmed: 37037824
doi: 10.1038/s41540-023-00272-x
pii: 10.1038/s41540-023-00272-x
pmc: PMC10086013
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

12

Informations de copyright

© 2023. The Author(s).

Références

Am J Respir Crit Care Med. 2020 May 15;201(10):1209-1217
pubmed: 32197050
FEMS Microbiol Rev. 2019 Mar 1;43(2):145-161
pubmed: 30657899
J Hosp Infect. 2018 Nov;100(3):e91-e97
pubmed: 30056016
J R Soc Interface. 2017 Jul;14(132):
pubmed: 28701506
J Fungi (Basel). 2022 Jan 18;8(2):
pubmed: 35205848
J Fungi (Basel). 2022 Mar 04;8(3):
pubmed: 35330266
Front Immunol. 2017 Nov 30;8:1692
pubmed: 29250071
mBio. 2020 Apr 14;11(2):
pubmed: 32291301
Thorax. 1992 Jun;47(6):437-40
pubmed: 1496503
Sci Rep. 2021 Jun 8;11(1):12039
pubmed: 34103589
Science. 2002 Mar 1;295(5560):1662-4
pubmed: 11872829
Osong Public Health Res Perspect. 2022 Feb;13(1):15-23
pubmed: 35255675
Cell Mol Life Sci. 2020 Feb;77(3):467-480
pubmed: 31776589
Trends Microbiol. 2001 Aug;9(8):382-9
pubmed: 11514221
Antimicrob Agents Chemother. 2001 Dec;45(12):3474-81
pubmed: 11709327
Int J Med Microbiol. 2011 Jun;301(5):436-44
pubmed: 21571589
Front Immunol. 2018 Apr 04;9:667
pubmed: 29670632
Front Microbiol. 2020 Aug 12;11:1951
pubmed: 32903715
Future Sci OA. 2016 Jul 06;3(2):FSO130
pubmed: 28670461
J Lab Clin Med. 1998 May;131(5):417-24
pubmed: 9605106
Clin Microbiol Infect. 2022 Apr;28(4):580-587
pubmed: 34454093
Adv Bioinformatics. 2010;:268925
pubmed: 21331364
Biomed Eng Online. 2020 Feb 12;19(1):9
pubmed: 32050989
J Theor Biol. 2008 Nov 21;255(2):163-75
pubmed: 18775440
Front Immunol. 2020 Sep 02;11:1911
pubmed: 33013842
J Investig Allergol Clin Immunol. 2008;18(3):156-62
pubmed: 18564625
Front Immunol. 2020 Mar 31;11:500
pubmed: 32296424
Cytometry A. 2014 Feb;85(2):126-39
pubmed: 24259441
Biomaterials. 2022 Apr;283:121420
pubmed: 35245733
mBio. 2020 Feb 4;11(1):
pubmed: 32019790
Curr Opin Microbiol. 2010 Aug;13(4):409-15
pubmed: 20627805
J Hosp Infect. 2021 Jul;113:145-154
pubmed: 33852950
Front Microbiol. 2020 Aug 20;11:1955
pubmed: 32973709
PLoS One. 2017 Oct 19;12(10):e0186422
pubmed: 29049319
Front Microbiol. 2015 May 28;6:503
pubmed: 26074897
Biofabrication. 2020 Feb 19;12(2):025012
pubmed: 31994489
N Engl J Med. 2009 Apr 30;360(18):1870-84
pubmed: 19403905
PLoS Comput Biol. 2014 Feb 20;10(2):e1003479
pubmed: 24586131
Curr Protoc Cytom. 2020 Dec;95(1):e80
pubmed: 33226733
J Infect Chemother. 2000 Sep;6(3):155-61
pubmed: 11810557
PLoS Comput Biol. 2021 Dec 13;17(12):e1009645
pubmed: 34898608
Am Rev Respir Dis. 1982 Jun;125(6):740-5
pubmed: 7091881
BMC Syst Biol. 2016 Mar 01;10:20
pubmed: 26927448
Front Microbiol. 2014 Feb 06;5:41
pubmed: 24567730
Clin Microbiol Rev. 2019 Nov 13;33(1):
pubmed: 31722890
BMC Syst Biol. 2016 Apr 21;10:34
pubmed: 27098278
Front Immunol. 2022 Aug 16;13:954985
pubmed: 36052094
Cell. 2005 May 20;121(4):511-513
pubmed: 15907465
Front Immunol. 2019 Feb 05;10:142
pubmed: 30804941
Front Microbiol. 2015 Jun 19;6:608
pubmed: 26150807
J Immunol. 2002 Feb 15;168(4):1919-25
pubmed: 11823527
Virulence. 2021 Dec;12(1):1980-1996
pubmed: 34338598
Clin Microbiol Infect. 2006 Apr;12(4):376-80
pubmed: 16524415
Infection. 2022 Feb;50(1):43-56
pubmed: 34570355
J Hosp Infect. 1994 Jan;26(1):27-35
pubmed: 7910180
PLoS One. 2009;4(3):e4891
pubmed: 19305493
Crit Care. 2015 Jan 12;19:7
pubmed: 25928694
Microorganisms. 2020 Apr 16;8(4):
pubmed: 32316261
Am J Respir Cell Mol Biol. 2017 Jul;57(1):66-76
pubmed: 28257233
Am J Respir Cell Mol Biol. 1992 Feb;6(2):235-43
pubmed: 1540387
Am J Respir Crit Care Med. 2004 Jan 1;169(1):120-4
pubmed: 14512270
Clin Microbiol Rev. 1999 Apr;12(2):310-50
pubmed: 10194462
Open Forum Infect Dis. 2020 Jun 19;7(7):ofaa242
pubmed: 32754626
Front Microbiol. 2012 Apr 26;3:129
pubmed: 22557995
J Exp Med. 1979 Jun 1;149(6):1504-18
pubmed: 448291
Sci Rep. 2016 Jun 13;6:27807
pubmed: 27291424
PLoS One. 2014 Oct 31;9(10):e111630
pubmed: 25360787
J Clin Microbiol. 1998 Jun;36(6):1494-500
pubmed: 9620367
Neural Netw. 2015 Jan;61:85-117
pubmed: 25462637
Stud Mycol. 2021 May 10;100:100115
pubmed: 34035866
J Fungi (Basel). 2021 Jun 07;7(6):
pubmed: 34200399
PLoS One. 2021 Apr 1;16(4):e0249372
pubmed: 33793643

Auteurs

Christoph Saffer (C)

Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Jena, Germany.
Faculty of Biological Sciences, Friedrich Schiller University Jena, Jena, Germany.

Sandra Timme (S)

Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Jena, Germany.

Paul Rudolph (P)

Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Jena, Germany.
Faculty of Biological Sciences, Friedrich Schiller University Jena, Jena, Germany.

Marc Thilo Figge (MT)

Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Jena, Germany. thilo.figge@leibniz-hki.de.
Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University Jena, Jena, Germany. thilo.figge@leibniz-hki.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH